July 18, 2017
Boston Scientific announces RANGER™ Drug-Coated Balloon new Long Lenghts.
The Ranger™ Drug-Coated Balloon is now available in long lengths up to 200mm. Simplify your SFA procedures by treating long lesions with a single DCB! Find out more about Ranger Long Length.
April 25, 2017
Boston Scientific announces favorable 12-month data for Ranger™
Boston Scientific today announced results from the RANGER SFA trial for the Ranger™ Paclitaxel-Coated PTA Balloon Catheter at the Charing Cross Symposium, in London. Data demonstrated that the drug-coated balloon (DCB) exhibited both a high rate of primary patency and freedom from target lesion revascularization (TLR) at 12 months, reducing the need for re-interventions to re-establish flow in previously blocked blood vessels.
January 31, 2017
Boston Scientific drives the DET debate at LINC 2017 symposium
Boston Scientific Drug-Eluting Technology was among the highlights at LINC 2017 with a comprehensive symposium on redefining SFA treatment and discussions on key topics such as its bold clinical trial program and the prospects for drug-eluting technology in Europe.
September 1, 2016
Sustained drug-release may hold the key to long-term efficacy in the SFA
Prof. Stefan Muller-Hulsbeck, principal investigator of the MAJESTIC clinical trial, provides his expert opinion on the importance of sustained drug-release in the treatment of SFA lesions.
August 23, 2016
Eluvia demonstrates better inhibition of neointimal formation compared to BMS
Results from a preclinical study evaluating the arterial response to paclitaxel and showed that the Eluvia stent was better at inhibiting neointimal formation compared to bare-metal stents.
February 22, 2016
Eluvia Drug-Eluting Vascular Stent receives CE Mark
Boston Scientific has received CE Mark for the Eluvia Drug-Eluting Vascular Stent and announces the initiation of the IMPERIAL head-to-head clinical trial comparing Eluvia to the Zilver PTX drug-coated stent.